Cress Lab UACC
@cresslabuacc.bsky.social
This page is for Dr. Anne Cress's lab at the University of Arizona Cancer Center. Cress Lab studies adhesion molecules, specifically laminin-binding integrins, and their role in early stage prostate cancer growth and proliferation.
https://acresslab.com/
https://acresslab.com/
Reposted by Cress Lab UACC
Well, this happened yesterday...
www.drugdiscoverytrends.com/nih-announce...
I assume that this pertains only to applications that focus on therapeutic development and not those addressing fundamental biology or mechanism.
But I am wary about making assumptions...
1/2
www.drugdiscoverytrends.com/nih-announce...
I assume that this pertains only to applications that focus on therapeutic development and not those addressing fundamental biology or mechanism.
But I am wary about making assumptions...
1/2
NIH announces end to funding for animal-only studies - Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
www.drugdiscoverytrends.com
July 8, 2025 at 12:25 PM
Well, this happened yesterday...
www.drugdiscoverytrends.com/nih-announce...
I assume that this pertains only to applications that focus on therapeutic development and not those addressing fundamental biology or mechanism.
But I am wary about making assumptions...
1/2
www.drugdiscoverytrends.com/nih-announce...
I assume that this pertains only to applications that focus on therapeutic development and not those addressing fundamental biology or mechanism.
But I am wary about making assumptions...
1/2
there is a new preprint from our collaborator, Dr. Beatrice Knudsen, at the University of Utah
Comparison of QuPath and HALO platforms for analysis of the tumor microenvironment in prostate cancer
QuPath, an open-source digital pathology platform, has gained widespread use for image analysis in biomedical research since its release in 2016. However, its reproducibility and reliability compared ...
pmc.ncbi.nlm.nih.gov
June 10, 2025 at 9:20 PM
there is a new preprint from our collaborator, Dr. Beatrice Knudsen, at the University of Utah
here is a new paper from the new Director of the UA Cancer Center, Dr. Dan Theodorescu
Concurrent loss of the Y chromosome in cancer and T cells impacts outcome - Nature
Comprehensive pan-cancer analysis of loss of the Y chromosome (LOY) in benign and malignant cells establishes a new model linking LOY in circulating and tumour-infiltrating immune cells to LOY in...
www.nature.com
June 6, 2025 at 4:41 PM
here is a new paper from the new Director of the UA Cancer Center, Dr. Dan Theodorescu
we are past 500 views and we only just this week got a PMID in PubMed
Frontiers | Intermediate risk prostate tumors contain lethal subtypes
url.usb.m.mimecastprotect.com
March 27, 2025 at 7:28 PM
we are past 500 views and we only just this week got a PMID in PubMed
my colleague, Dr. Noel Warfel, with his post-doc, Dr. Amber Clements, have found a way to make prostate cancer more vulnerable to immunotherapies by inhibiting PIM1
Study finds new potential for prostate cancer immunotherapy
A new study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined wit...
medicalxpress.com
March 6, 2025 at 6:36 PM
my colleague, Dr. Noel Warfel, with his post-doc, Dr. Amber Clements, have found a way to make prostate cancer more vulnerable to immunotherapies by inhibiting PIM1
the NIH/NCI study section in which I was a reviewer that was scheduled for tomorrow and Friday was canceled this morning
February 19, 2025 at 7:41 PM
the NIH/NCI study section in which I was a reviewer that was scheduled for tomorrow and Friday was canceled this morning
Reposted by Cress Lab UACC
You can use this website to look up how much money goes into your state from NIH, how many jobs are supported, and more.
www.unitedformedicalresearch.org/nih-in-your-...
www.unitedformedicalresearch.org/nih-in-your-...
NIH In Your State - United For Medical Research
Select a state on the map to see the impact of NIH funding across America.
www.unitedformedicalresearch.org
January 22, 2025 at 10:48 PM
You can use this website to look up how much money goes into your state from NIH, how many jobs are supported, and more.
www.unitedformedicalresearch.org/nih-in-your-...
www.unitedformedicalresearch.org/nih-in-your-...
a new review from our scientific writer/editor, William Harryman (wharryman.bsky.social), in Frontiers in Urology, highlighting aggressive subtypes in intermediate risk prostate cancer
Frontiers | Intermediate risk prostate tumors contain lethal subtypes
www.frontiersin.org
January 15, 2025 at 3:59 PM
a new review from our scientific writer/editor, William Harryman (wharryman.bsky.social), in Frontiers in Urology, highlighting aggressive subtypes in intermediate risk prostate cancer
Reposted by Cress Lab UACC
Z-stacking thru a goblet cell stained enteroid #immunofluorescence #microscopy
December 10, 2024 at 10:07 PM
Z-stacking thru a goblet cell stained enteroid #immunofluorescence #microscopy
recent abstract from Cress Lab for the AACR Liquid Biopsy Conference in San Diego
Abstract A055: Tumor muscle invasion promotes tumor heterogeneity and normal muscle reprogramming
Abstract. Aggressive human prostate tumors traverse a contractile smooth muscle pseudo-capsule, in a process termed extracapsular extension (ECE), defining the pT3 pathologic stage associating with in...
aacrjournals.org
November 21, 2024 at 8:11 PM
recent abstract from Cress Lab for the AACR Liquid Biopsy Conference in San Diego
a recent preprint from our collaborator, Dr. Noel Warfel
Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy
Immunotherapy has changed the treatment paradigm for many types of cancer, but immune checkpoint inhibitors (ICIs) have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to ...
www.biorxiv.org
November 21, 2024 at 4:56 PM
a recent preprint from our collaborator, Dr. Noel Warfel